An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
Megadott ok: Replaced it with another clinical trial
Key facts
- Where
- Allentown, Aurora, Bakersfield, Boston, Chapel Hill, Charlotte, Daphne, Fargo, Fullerton, Lakewood, Los Angeles, Marietta, Miami, New Brunswick, Redondo Beach, Santa Barbara, Sioux Falls, St Louis, Tampa és Vancouver, Egyesült ÁllamokSee the 20 sites
- Phase
- 2. fázis
Where in Egyesült Államok
- AllentownAllentown, Egyesült ÁllamokNo longer taking part
- AuroraAurora, Egyesült ÁllamokNo longer taking part
- BakersfieldBakersfield, Egyesült ÁllamokNo longer taking part
- BostonBoston, Egyesült ÁllamokNo longer taking part
- Chapel HillChapel Hill, Egyesült ÁllamokNo longer taking part
- CharlotteCharlotte, Egyesült ÁllamokNo longer taking part
- DaphneDaphne, Egyesült ÁllamokNo longer taking part
- FargoFargo, Egyesült ÁllamokNo longer taking part
- FullertonFullerton, Egyesült ÁllamokNo longer taking part
- LakewoodLakewood, Egyesült ÁllamokNo longer taking part
- Los AngelesLos Angeles, Egyesült ÁllamokNo longer taking part
- MariettaMarietta, Egyesült ÁllamokNo longer taking part
- MiamiMiami, Egyesült ÁllamokNo longer taking part
- New BrunswickNew Brunswick, Egyesült ÁllamokNo longer taking part
- Redondo BeachRedondo Beach, Egyesült ÁllamokNo longer taking part
- Santa BarbaraSanta Barbara, Egyesült ÁllamokNo longer taking part
- Sioux FallsSioux Falls, Egyesült ÁllamokNo longer taking part
- St LouisSt Louis, Egyesült ÁllamokNo longer taking part
- TampaTampa, Egyesült ÁllamokNo longer taking part
- VancouverVancouver, Egyesült ÁllamokNo longer taking part
Trial details
- Who runs it
- Bristol-Myers Squibb
- Trial code
- NCT03704077
- Record updated
- 2020. május 19.
- Original description
The purpose of this study is to determine the effectiveness of relatlimab plus nivolumab, alone or in combination with various standard-of-care treatments in participants with gastric cancer (GC) or gastroesophageal junction (GEJ) adenocarcinoma that has come back or spread to other places in the body after prior therapy.Read full original descriptionShow less
A Randomized, Active-Controlled, Open-Label, Phase 2 Clinical Trial of BMS-986213, in Combination With Various Standard-of-Care Therapeutic Regimens, in Participants With Recurrent, Locally Advanced, or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction (GEJ) Adenocarcinoma
The purpose of this study is to determine the effectiveness of relatlimab plus nivolumab, alone or in combination with various standard-of-care treatments in participants with gastric cancer (GC) or gastroesophageal junction (GEJ) adenocarcinoma that has come back or spread to other places in the body after prior therapy.
Inclusion: Histologically or cytologically confirmed locally advanced or recurrent or metastatic GC or GEJ adenocarcinoma that is considered incurable by local therapies such as radiation or surgery; Evidence of progressive disease (PD) on at least one prior platinum- and fluoropyrimidine-containing chemotherapy regimen; Available tumor tissue for biomarker analysis.
Exclusion: Uncontrolled or significant cardiovascular disease; Other protocol defined inclusion/exclusion criteria could apply; Must not have squamous cell or undifferentiated GC or GEJ; Untreated known central nervous system (CNS) metastases.
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com.